Drug Trial Radar · NCT06152575
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
492
Planned (sponsor's estimate)
Start
Feb 8, 2024
Primary completion
Aug 26, 2026
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment. Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM. Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study. The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as: * a shot under the skin at the study clinic * through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects. Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits). The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is.
Conditions
- Multiple Myeloma
Interventions
ElranatamabDrug
Elranatamab will be administered subcutaneously
ElotuzumabDrug
Elotuzumab will be administered intravenously
PomalidomideDrug
Pomalidomide will be administered orally
DexamethasoneDrug
Dexamethasone will be administered orally
BortezomibDrug
Bortezomib will be administered subcutaneously or intravenously
CarfilzomibDrug
Carfilzomib will be administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival per International Myeloma Working Group criteriaTime frame: Up to approximately 5 years
Locations
268 sites in 27 countries. Site status is shown where the registry gives one.
Infirmary Cancer Care
Mobile, Alabama · Recruiting
Beverly Hills Cancer Center
Beverly Hills, California · Recruiting
Clovis Community Medical Center
Clovis, California · Recruiting
Community Cancer Institute
Clovis, California · Recruiting
Clinical Research Advisors (Encino Satellite Location)
Encino, California · Recruiting
University of California San Francisco
Fresno, California · Recruiting
Community Regional Medical Center
Fresno, California · Recruiting
Hoag Health Center Irvine
Irvine, California · Active not recruiting
Hoag Hospital Irvine
Irvine, California · Active not recruiting
Clinical Research Advisors (Korea Town Satellite Location)
Los Angeles, California · Recruiting
Clinical Research Advisors (West Hollywood Satellite Location)
Los Angeles, California · Recruiting
Valkyrie Clinical Trials
Los Angeles, California · Recruiting
Hoag Memorial Hospital Presbyterian
Newport Beach, California · Active not recruiting
Mission Community Hospital (Satellite Site)
Panorama City, California · Recruiting
University of California Davis (UC Davis) Comprehensive Cancer Center
Sacramento, California · Recruiting
University of California
Sacramento, California · Recruiting
UCHealth Poudre Valley Hospital
Fort Collins, Colorado · Recruiting
UCHealth Harmony
Fort Collins, Colorado · Recruiting
UCHealth Greeley Hospital
Greeley, Colorado · Recruiting
UCHealth Longs Peak Hospital
Longmont, Colorado · Recruiting
UCHealth Longs Peak Medical Center
Longmont, Colorado · Recruiting
UCHealth - Medical Center of the Rockies
Loveland, Colorado · Recruiting
Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center
Coral Gables, Florida · Recruiting
University of Miami Hospital and Clinics - Deerfield Beach
Deerfield Beach, Florida · Recruiting
Sylvester Comprehensive Cancer Center- Doral
Doral, Florida · Recruiting
Sylvester Comprehensive Cancer Center - Hollywood
Hollywood, Florida · Recruiting
Sylvester Comprehensive Cancer Center
Miami, Florida · Recruiting
University of Miami Hospital and Clinics - Griffin Cancer Research Building
Miami, Florida · Recruiting
University of Miami Hospital and Clinics
Miami, Florida · Recruiting
Baptist Hospital of Miami
Miami, Florida · Recruiting
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida · Recruiting
Sylvester Comprehensive Cancer Center- Kendall
Miami, Florida · Recruiting
BRCR Global
Plantation, Florida · Recruiting
BRCR Medical Center Inc
Plantation, Florida · Recruiting
Brcr Medical Center, Inc.
Plantation, Florida · Recruiting
HCA Florida Westside Hospital
Plantation, Florida · Recruiting
BRCR Medical Center Inc.
Tamarac, Florida · Recruiting
Endeavor Health - Swedish Hospital
Chicago, Illinois · Recruiting
Endeavor Health - Evanston Hospital
Evanston, Illinois · Recruiting
Endeavor Health - Glenbrook Hospital Ambulatory Care Center
Glenview, Illinois · Recruiting
Showing 40 of 268 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.